Home    Back

 223. Primary membranoproliferative glomerulonephritis
 [ 13 clinical trials,    12 drugs(DrugBank: 5 drugs),    10 target genes / 38 target pathways

Searched query = "Primary membranoproliferative glomerulonephritis", "Dense deposit disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03459443June 20, 201830 September 2019A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471C3 Glomerulonephritis;C3 Glomerulopathy;Immune Complex Membranoproliferative Glomerulonephritis;IC-MPGN;Dense Deposit DiseaseDrug: ACH-0144471Achillion PharmaceuticalsNot recruiting17 Years65 YearsAll22Phase 2United States;Australia;Belgium;Italy;Netherlands
2NCT03369236June 12, 20182 September 2019A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G)A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G)C3 Glomerulopathy;C3 Glomerulonephritis;Dense Deposit DiseaseDrug: ACH-0144471;Drug: PlaceboAchillion PharmaceuticalsNot recruiting17 Years65 YearsAll13Phase 2United States;United Kingdom
3NCT03453619January 22, 201828 January 2019Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesA Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)IgA Nephropathy;Lupus Nephritis;Membranous Nephropathy;C3 Glomerulonephritis;Dense Deposit DiseaseDrug: APL-2Apellis Pharmaceuticals, Inc.Recruiting18 YearsN/AAll48Phase 2United States
4EUCTR2017-001821-42-BE15/01/201828 February 2019A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy.A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 GlomerulopathyC3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN).
MedDRA version: 20.0 Level: PT Classification code 10077827 Term: C3 glomerulopathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Avacopan
Product Code: CCX168
Pharmaceutical Form: Capsule
INN or Proposed INN: AVACOPAN
CAS Number: 1346623-17-3
Current Sponsor code: CCX168
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
ChemoCentryx, Inc.Authorised Female: yes
Male: yes
88Phase 2France;United States;Canada;Spain;Belgium;Ireland;Denmark;Netherlands;Germany;Italy;United Kingdom
5NCT03124368August 9, 201711 November 2019A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGNA Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)C3 Glomerulonephritis;Dense Deposit Disease;Membranoproliferative Glomerulonephritis, Type II;C3 Glomerulopathy;Immune Complex Mediated Membranoproliferative GlomerulonephritisDrug: ACH-0144471Achillion PharmaceuticalsNot recruiting16 Years65 YearsAll6Phase 2Australia;Belgium;Netherlands
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03180723July 1, 201716 December 2017Effect of Rituximab in Treatment of Membranoproliferative GlomerulonephritisEffect of Rituximab in Treatment of Primary Membranoproliferative GlomerulonephritisMembranoproliferative GlomerulonephritisDrug: Rituximab;Drug: CyclosporinAssiut UniversityNot recruiting18 YearsN/AAll30Phase 3
7NCT02682407February 201622 January 2018Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit DiseaseIgAN;Lupus Nephritis;MN;C3GBiological: OMS721;Other: Vehicle (D5W)Omeros CorporationRecruiting18 YearsN/AAll44Phase 2United States
8NCT02302755November 20147 November 2016TP10 Use in Patients With C3 Glomerulopathy (C3G)A Pilot, Open-Label Single Center Trial of TP10 in Pediatric and Adult Patients With C3 Glomerulopathy (C3G)Dense Deposit DiseaseDrug: TP10University of IowaNot recruiting4 YearsN/ABoth0Phase 1United States
9NCT02093533March 201429 January 2018Eculizumab in Primary MPGNEVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIAMembranoproliferative GlomerulonephritisDrug: EculizumabMario Negri Institute for Pharmacological ResearchAlexion Pharma Italy s.r.l.Not recruitingN/A75 YearsAll10Phase 2Italy
10EUCTR2013-003826-10-IT24/01/201419 February 2018ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITISEVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA - Eculizumab in primary MPGNMembranoproliferative glomerulonephritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Soliris
Product Name: Soliris
Pharmaceutical Form: Concentrate for solution for injection/infusion
INN or Proposed INN: ECULIZUMAB
CAS Number: 219685-50-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
IRCCS- Mario Negri InstituteNot RecruitingFemale: yes
Male: yes
10Phase 2Italy
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01791686January 201319 February 2015Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit DiseaseA Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit DiseaseDense Deposit Disease;Membranoproliferative Glomerulonephritis Type II;C3 GlomerulonephritisDrug: CDX-1135Celldex TherapeuticsNot recruiting4 YearsN/ABoth1Phase 1United States
12NCT01221181July 20104 March 2019Eculizumab Therapy for Dense Deposit Disease and C3 NephropathyEculizumab Therapy for Dense Deposit Disease and C3 NephropathyDense Deposit Disease;Membranoproliferative GlomerulonephritisDrug: EculizumabColumbia UniversityAlexion PharmaceuticalsNot recruiting18 YearsN/AAll6Phase 1United States
13NCT00583427December 200729 June 2015Sulodexide Treatment in Patients With Dense Deposit DiseaseSulodexide Treatment in Patients With Dense Deposit DiseaseDense Deposit DiseaseDrug: SulodexideUniversity of IowaNot recruiting5 Years20 YearsBoth0Phase 1United States

Back to top